ANL 16.20 Decreased By ▼ -0.18 (-1.1%)
ASC 14.63 Increased By ▲ 0.95 (6.94%)
ASL 20.04 Decreased By ▼ -0.41 (-2%)
BOP 8.55 Decreased By ▼ -0.05 (-0.58%)
BYCO 7.53 Increased By ▲ 0.24 (3.29%)
FCCL 17.50 Increased By ▲ 0.11 (0.63%)
FFBL 23.15 Increased By ▲ 1.68 (7.82%)
FFL 15.25 Increased By ▲ 0.35 (2.35%)
FNEL 7.35 Increased By ▲ 0.05 (0.68%)
GGGL 17.15 Increased By ▲ 0.74 (4.51%)
GGL 29.95 Increased By ▲ 0.10 (0.34%)
HUMNL 5.96 Increased By ▲ 0.17 (2.94%)
JSCL 20.68 Increased By ▲ 0.28 (1.37%)
KAPCO 28.99 Increased By ▲ 0.31 (1.08%)
KEL 3.48 Increased By ▲ 0.03 (0.87%)
MDTL 2.11 Decreased By ▼ -0.09 (-4.09%)
MLCF 33.60 Increased By ▲ 0.18 (0.54%)
NETSOL 106.00 Decreased By ▼ -1.55 (-1.44%)
PACE 4.33 Decreased By ▼ -0.17 (-3.78%)
PAEL 27.95 Increased By ▲ 0.75 (2.76%)
PIBTL 8.70 Increased By ▲ 0.10 (1.16%)
POWER 6.90 Decreased By ▼ -0.03 (-0.43%)
PRL 17.18 Increased By ▲ 0.87 (5.33%)
PTC 9.30 Increased By ▲ 0.12 (1.31%)
SILK 1.44 No Change ▼ 0.00 (0%)
SNGP 42.33 Increased By ▲ 0.27 (0.64%)
TELE 16.45 Decreased By ▼ -0.09 (-0.54%)
TRG 135.78 Decreased By ▼ -2.22 (-1.61%)
UNITY 29.90 Increased By ▲ 1.40 (4.91%)
WTL 2.40 Decreased By ▼ -0.05 (-2.04%)
BR100 4,668 Increased By ▲ 50.21 (1.09%)
BR30 20,892 Increased By ▲ 107.28 (0.52%)
KSE100 44,822 Increased By ▲ 487.85 (1.1%)
KSE30 17,521 Increased By ▲ 178.45 (1.03%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,252
2424hr
Pakistan Cases
1,263,664
89324hr
1.7% positivity
Sindh
465,175
Punjab
437,572
Balochistan
33,114
Islamabad
106,402
KPK
176,650

FRANKFURT: Pfizer and BioNTech on Monday said trial results showed their coronavirus vaccine was safe and produced a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.

The vaccine would be administered at a lower dosage than for people over 12, they said.

“In participants five to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralising antibody responses,” US giant Pfizer and its German partner said in a joint statement.

They plan to submit their data to regulatory bodies in the European Union, the United States and around the world “as soon as possible”.

The trial results are the first of their kind for children under 12, with a Moderna trial for six-11 year olds still ongoing.

Both the Pfizer and Moderna jabs are already being administered to adolescents over 12 and adults in countries around the globe.

Although children are considered less at risk of severe Covid, there are concerns that the highly contagious Delta variant could lead to more serious cases.

Innoculating children is also seen as key to keeping schools open and helping end the pandemic.

“We are eager to extend the protection afforded by the vaccine to this younger population,” said Pfizer CEO Albert Bourla, noting that “since July, paediatric cases of COVID-19 have risen by about 240 percent in the US”.

Kids in the 5-11 age trial group received a two-dose regimen of 10 microgrammes in the trial, compared with 30 microgrammes for older age groups, the companies said. The shots were given 21 days apart.

The 10 microgramme dose was “carefully selected as the preferred dose for safety, tolerability and immunogenicity” for that age group, the statement said. The side effects were “generally comparable to those observed in participants 16 to 25 years of age”, it added.

Among the most commonly reported side effects in the past have been pain and swelling at the injection site as well as headache, chills and fever.

Israel has already given special authorisation to vaccinate children aged 5-11 who are “at significant risk of serious illness or death” from Covid, using the Pfizer jab at the lower dosage.

Pfizer and BioNTech are also trialling their vaccine on infants aged six months to two years, and on children aged two to five.

The topline results for those trials are expected “as soon as” the fourth quarter of this year, the companies said.

All together, up to 4,500 children aged six months to 11 years have enrolled in the Pfizer-BioNTech trials in the US, Finland, Poland and Spain.

Like its Moderna rival, the Pfizer jab is based on novel mRNA technology that delivers genetic instructions to cells to build the coronavirus spike protein, in order to evoke antibodies when bodies encounter the real virus.

Comments

Comments are closed.